A multicenter study of allogeneic HSCT in Nijmegen breakage syndrome with conditioning regimen based on reduced doses of treosulfan
In brief
Nijmegen breakage syndrome transplant survival was 91% in children under 8
In this 41-patient multicenter study, overall survival was 91% among those transplanted before age 8, compared with 59% among older patients. Survival and other outcomes did not differ significantly between the 21 and 30 g/m2 treosulfan regimens, and no graft failures occurred. The findings support considering transplant early, but longer follow-up is needed to assess relapse and secondary cancers.
- Journal
- Transplantation and cellular therapy (Q1)
- Published
- 16 November 2026
- Study design
- Unclassified
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- A Laberko, E Skorobogatova, O Slesarchuk, I Vlasova, L Vakhonina, L Shelikhova, et al.
- PMID
- 43039234
- DOI
- 10.1016/j.jtct.2026.11.030
Why clinicians should know about it
- Picked for Hematology (paper of the day, 20 November 2026): Multicentre allogeneic transplant outcomes in Nijmegen breakage syndrome
Abstract
BACKGROUND: Nijmegen breakage syndrome (NBS) is a DNA repair disorder characterized by combined immunodeficiency and increased susceptibility to lymphoid malignancies. Allogeneic hematopoietic stem cell transplantation (HSCT) is used to cure immunodeficiency and prevent lymphoid malignancies in NBS. Minimal intensity conditioning is an option of choice to prevent HSCT-associated toxicity. OBJECTIVE: We report a multicenter study of HSCT in NBS using different low dose exposures to treosulfan. METHODS: 41 patients were included: 16 received treosulfan 30 and 25 - 21 g/m2, all in combination with fludarabine, 24 with cyclophosphamide 20-40 mg/kg. In 25 patients, 9-10/10 matched unrelated, in 10 mismatched related and in 6 matched sibling donor was used. In 19 patients TCRαβ/CD19 depletion, in 15 post-transplant cyclophosphamide (25-80 mg/kg), in 7 patients no T-cell depletion was used. RESULTS: The median FU time in 33 survivors was 3,5 years (range 0,8-9). OS was 0,81 (95% CI 0,62-1,0) and in 0,77 (95% CI 0,58-0,95) (p=0,77) after treosulfan 30 and 21g/m2 respectively. Deaths, secondary malignancy (n=2, all after treosulfan 30 g/m2) and leukemia relapse (n=4, all after treosulfan 21 g/m2) were considered for events; EFS was 0,75 (95% CI 0,54-0,96) and 0,67 (95% CI 0,46-0,88) (p=0,51) after treosulfan 30 and 21 g/m2 respectively. No patient in either group developed graft failure. No significant differences in incidence of severe organ toxicity, acute and chronic GVHD, viral reactivations and mixed chimerism were observed. OS was 0,91 (95% CI 0,8-1,0) in those who were younger than 8 years of age (n=23) and 0,59 (95% CI 0,33-0,85) in those older than 8 years (n=18), p=0,04. CONCLUSION: Treosulfan-based conditioning regimen is well tolerated in NBS with no significant differences in HSCT outcomes between those receiving treosuflan 21 or 30g/m2. Two cases of secondary malignancy were observed after treosulfan 30g/m2 and four cases of leukemia relapse after treosulfan 21g/m2. HSCT in NBS should be considered early in life.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.